Abstract Abstract #76 Background: QOL and MH outcomes were integrated into the NSABP B-30 trial as secondary outcomes to the efficacy analyses which are being presented separately. Explicit secondary aims of the NSABP B-30 study were 1) to compare toxicities among the regimens, 2) to compare QOL, and 3) to examine differences in amenorrhea and its relationship to symptoms, QOL, and efficacy. Here we examine the secondary aims of the study as a companion to the efficacy results that are presented separately.
 Materials and Methods: 5351 pts with cT1-3, N0-1, M0 were enrolled from 3/1/99 to 3/31/2004. 2170 were enrolled on the QOL study, and 2449 were enrolled on the MH study and were randomized to one of three treatment groups: Group 1 [doxorubicin (A) 60 mg/m2 and C 600 mg/m2 q 3 weeks (wks) x 4 followed by docetaxel (T) 100 mg/m2 q 3 wks x 4; Group 2 [A 50 mg/m2 and T 75 mg/m2 q 3 wks x 4]; Group 3 [A 50 mg/m2 T 75 mg/m2 and cyclophosphamide (C) 500 mg/m2 q 3 wks x 4]. All patients with ER-positive tumors received hormonal therapy after completing chemotherapy. Preliminary results from Group 1 have been reported previously (Swain, et al. Breast Cancer Res Treat, 2008).
 Results: The protocol specifies that 800 deaths are required for the definitive analysis of treatment, QOL, and MH outcomes, which are expected to occur by fall 2008. For this final report, results from a comparison of the three arms will be analyzed and presented. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 76.
Abstract Abstract #3099 Background: Molecular marker expression analyses have led to the identification of unique breast cancer subtypes that have clinical and prognostic importance. Using data from a large population-based breast cancer cohort, we report results examining combined HER2/neu and estrogen receptor (ER) subtype distribution in relation to patient and tumor characteristics as well as breast cancer specific survival.
 Methods: We conducted a retrospective cohort study of 1,645 female members of a large managed care organization newly diagnosed with invasive breast cancer from 1988 to 1995. We collected patient, tumor, treatment, and outcome information from medical records and electronic cancer registry files. We used immunohistochemistry techniques to evaluate gene expression of specific molecular markers including HER2/neu and estrogen receptor (ER). We examined prevalence of markers as well as odds ratios (OR) and 95% confidence intervals (CI) comparing outcomes by marker expression.
 Results: Women with HER2+/ER- tumors were more likely to have been diagnosed at a younger age (less than age 60) than women with luminal A subtype (HER2-, ER+ and/or PR+) tumors (65.5% versus 47.8%, P<0.0001). A higher proportion of women with HER2+/ER- tumors were other than white race compared with women with luminal A subtype (21.8% versus 11.6%, P=0.007). Women with luminal B (HER2+, ER+ and/or PR+) or basal-like (HER2-, ER-, PR) subtype tumors were similarly more likely to be older at diagnosis and from minority backgrounds than women with luminal A subtype. Family history of breast cancer was not clearly associated with HER2/ER subtype. Women with luminal A tumors were more likely to be diagnosed with stage 1 disease than women with other tumor subtypes (luminal A: 56.3%; luminal B: 38.9%; basal-like: 38.1%; HER2+/ER-: 25.5%; P<0.0001). Residual tumor in surgical margins was not associated with HER2/ER subtype. Compared with women with luminal A tumors, women with HER2+/ER- tumors were much more likely to die of their cancers overall (OR=6.5, CI=3.5-11.9), and by stage (stage 1: OR=11.5, CI=2.6-50.3; stage 2: OR=3.8, CI=1.6-9.2; stage 3/4: OR=9.0, CI=1.1-77.2). Odds of breast cancer death, overall and by stage, was also increased for women with luminal B and basal-like subtype tumors compared with women having luminal A subtype.
 Conclusions: HER2/ER subtype was clearly associated with patient as well as tumor characteristics in this large cohort of breast cancer patients. Specific tumor subtypes (HER2+/ER-, luminal B, and basal-like) were also associated with increased likelihood of dying of breast cancer. Further work is warranted to define treatment strategies by molecular subtypes. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3099.
